Bronchodilator Drugs - United Arab Emirates

The projected revenue for the Bronchodilator Drugs market in the United Arab Emirates is expected to reach US$55.30m in 2024.
This market is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 4.85%, leading to a market volume of US$70.08m by 2029.
When compared globally, United States is forecasted to generate the highest revenue in this market, amounting to US$17.34bn in 2024.
Bronchodilator drug usage in the United Arab Emirates has seen a significant increase due to the high prevalence of respiratory diseases in the region.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are commonly used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In United Arab Emirates, the market for bronchodilator drugs has been growing steadily in recent years.

Customer preferences: The preference for bronchodilator drugs in United Arab Emirates is driven by the high prevalence of respiratory diseases, particularly asthma. According to the World Health Organization (WHO), asthma is a major public health concern in the country, affecting around 13% of the population. As a result, there is a high demand for bronchodilator drugs among patients suffering from asthma and other respiratory diseases.

Trends in the market: The bronchodilator drugs market in United Arab Emirates is characterized by the presence of both international and local pharmaceutical companies. The market is dominated by international players who offer a wide range of products to cater to the diverse needs of patients. However, there is also a growing trend towards the use of locally produced generic drugs, which are more affordable and accessible to patients.

Local special circumstances: One of the key factors driving the growth of the bronchodilator drugs market in United Arab Emirates is the government's focus on improving healthcare infrastructure and services. The government has invested heavily in the healthcare sector in recent years, with a particular emphasis on the prevention and treatment of chronic diseases such as asthma. This has led to an increase in the availability of healthcare facilities and services, including the availability of bronchodilator drugs.

Underlying macroeconomic factors: The growth of the bronchodilator drugs market in United Arab Emirates is also supported by favorable macroeconomic conditions. The country has a high per capita income and a well-developed healthcare system, which makes it an attractive market for pharmaceutical companies. In addition, the government's efforts to diversify the economy away from oil and gas have led to the growth of other sectors, including healthcare, which has further boosted the demand for bronchodilator drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.